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Albuminuria and the permselective properties of the
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Albuminuria and the permselective properties of the glomerulus
in cardiac failure. Fractional dextran clearances (OD) were used
to ascertain whether the albuminuria accompanying cardiac fail-
ure (CF) has a hemodynamic basis. In 17 patients with grade-tV
CF in whom GFR and effective renal plasma flow (ERPF) were
depressed to 58 7 and 215 20 mllmin/l.73 m2, respectively,
O was elevated relative to normal control subjects over the
Stokes-Einstein radius (r) interval of 28 to 46 A. For dextran of
equivalent size to albumin (r = 36 A), the rate of urinary excre-
tion (UD36V) was not increased because elevated O was offset
by the depressed GFR. In contrast, urinary albumin excretion
(UIbV) was increased to 82 35 g/min. Thus, for albuminuria
in CF to have the hemodynamic basis suggested by elevation of
O requires that (1) the fractional clearance for anionic albumin
be disproportionately enhanced relative to uncharged dextran by
reduced glomerular plasma flow and/or (2) that glomerular elec-
trostatic barrier function be impaired in CF. In seven patients
with minimal change nephropathy, U36V was similar to that in
CF, but UalbV was 40 times greater than that in CF. Thus, if
glomerular electrostatic barrier function is impaired in CF, such
dysfunction is trivial by comparison with minimal change ne-
phropathy.
Albuminurie et propriétés de permsélectivité du glomérule dans
l'insuffisance cardiaque. Les clearances fractionnelles de dextran
(OD) ont été employees pour rechercher si l'albuminurie de
l'insuffisance cardiaque a une base hémodynamique. Chez 17
malades atteints d'insuffisance cardiaque au stade IV chez les-
quels GFR et ERPF étaient abaissés a 58 7 et 215 20 mI/mini
1,73 m', respectivement, O était supérieur aux valeurs des con-
trôles normaux de l'intervalle de 28 a 46 A de rayon (r) de
Stokes-Einstein. Pour le dextran de taille equivalente a
l'albumine (r = 36 A), le debit urinaire (U6V) n'était pas aug-
menté car l'élévation de °D36 était annulée par Ia diminution du
debit de filtration glomérulaire. L'excrCtion d'albumine, au con-
traire, était augmentée a 82 35 g/min. Ainsi, pour que
l'albuminurie de l'insuffisance cardiaque ait Ia base hémodyna-
mique suggérCe par l'augmentation de il faudrait que (1)
l'clearance fractionnelle pour l'albumine anionique soit aug-
menté, hors de proportion par rapport au dextran neutre, par Ia
reduction du debit plasmatique glomérulaire etlou (2) que Ia bar-
rière électrostatique glomCrulaire soit altérée par CF. Chez 7
malades atteints de néphropathie avec des lesions morpholo-
giques minimes, U36V était semblable aux valeurs observées
dans l'insuffisance cardiaque, mais UaIbV était 40 fois plus grand.
Ainsi, même si la barriIre électrostatique glomCrulaire est al-
térée dans l'insuffisance cardiaque, une telle alteration est du
peu d'importance par comparaison avec Ia néphropathie a modi-
fications minimes.
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Proteinuria is frequently detectable in patients
with severe cardiac failure [1, 2]. The increased pas-
sage into the urine of plasma proteins the size of
albumin and larger is often taken to reflect a change
in permeability properties of the glomerular capil-
lary wall. Recent evidence indicates, however, that
the transglomerular passage of any given macro-
molecule is also governed by the convective and
diffusive forces acting across the glomerular capil-
lary wall [3, 4]. These forces, in turn, are appre-
ciably influenced by renal hemodynamic changes,
which in cardiac failure typically include depression
of renal plasma flow [5-8].
Using fractional clearances of macromolecules
and an analysis based on a hydrodynamic theory
of transport of macromolecules through an iso-
porous membrane, Brenner et al have recently ex-
amined the effects of selective perturbations of the
determinants of GFR on glomerular permselectivity
to macromolecules [3, 4]. According to this analy-
sis, increased sieving of macromolecules across the
glomerular capillary wall is predicted to occur when
glomerular plasma flow is depressed. This predic-
tion was subsequently validated for both uncharged
dextrans and anionic dextran sulfate during an an-
giotensin-Il-induced reduction in glomerular plasma
flow in the Munich-Wistar rat [9]. In another micro-
puncture study in the same species, angiotensin II
infusion was also associated with increased gb-
merular filtration and urinary excretion of endoge-
nous albumin [10].
Some circumstantial evidence exists to suggest
that altered glomerular pressures and flows rather
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than a change in physicochemical properties of the
glomerular capillaries might account for the protein-
uria of cardiac failure. This includes (1) the absence
of glomerular morphologic change in patients dying
of cardiac failure [1, 11—12], (2) the reversibility of
proteinuria when cardiac performance has been
rapidly improved by pericardiectomy in patients
with constrictive pericarditis [13—14], and (3) the in-
duction of transient proteinuria in rats during in-
fusion. of angiotensin II or norepinephrine [9—10,
15-16], which is accompanied by a depression of
renal blood flow similar to that seen in cardiac fail-
ure [17]. To evaluate the role of hemodynamic fac-
tors in inducing proteinuria, we have studied the
permselective properties of the glomerulus to a ho-
mologous series of neutral macrosolutes (dextrans)
in 17 patients with low-output cardiac failure. Our
findings form the basis of this report.
Methods
Seventeen patients with long-standing chronic
valvular heart disease or cardiomyopathy (ischemic
or idiopathic) were studied. Fifteen were males, and
two were females aged 18 to 65 years. Hyper-
tension, infective endocarditis, and known pre-
existing renal disease were excluded in each case.
All were hospitalized because of functional class-TV
heart failure as defined by the Criteria Committee of
the New York Heart Association. Therapy included
bedrest, sodium restriction, "loop" diuretics, and
afterload reduction with oral hydralazine or prazo-
sin (8 patients), or intravenous sodium nitro-
prusside (5 patients), respectively. Cardiac index,
determined within 24 hours of the macromolecule
clearance study in 14 patients, was uniformly low,
averaging 2.3 (sEM) 0.2 liters/min/m2 (normal,
2.8 to 4.2 liters/mm/rn2).
Two groups of subjects served as controls. "Nor-
mal controls" were seven healthy male and female
volunteers aged 20 to 64 years. They were devoid of
renal disease and hypertension as judged by a nega-
tive history, clinical examination, and urinalysis.
Nephrotic controls" were seven patients aged 20
to 61 years with biopsy-proven minimal change ne-
phropathy and with daily urinary protein excretions
in excess of 3.5 g. Informed consent was obtained
from each patient and volunteer prior to study. The
study protocol was approved by the Stanford Com-
mittee for the Protection of Human Subjects in Re-
search.
Study protocol. Each subject voided completely
prior to the i.v. bolus administration of inulin, 60 mg/
kg (Arnar Stone Laboratories), and dextran 40, 65 to
130 mg/kg (Rheomacrodex, Pharmacia). In cardiac
and nephrotic patients, para-aminohippurate (PAH)
(Merck, Sharp, and Dohme), 24 mg/kg, was added to
the bolus. At the end of a 40- to 60-mm equilibration
period, the bladder was again emptied by voiding,
after which two to five carefully timed urine collec-
tions were made. Venous blood was sampled at 3,
10, 20, and 40 mm following the bolus and thereafter
to bracket each urine collection until at least 180
mm had elapsed. Because of uncertainty regarding
the accuracy of urine collection with spontaneous
voiding, GFR and effective renal plasma flow
(ERPF) were determined from the biexponential
plasma decay curves of inulin and PAH, with the
equation
GFR or ERPF = amount of inulin
or PAH injected (a/3/A/3 + B) (1)
where A is the y intercept and a the slope of the
initial phase of the drug distribution, and B is the y
intercept and f3 the slope of elimination of inulin
(GFR) or PAH (ERPF), respectively [18].
Fractional clearances of dextran 40 (OD) were de-
termined from plasma and urine obtained during the
first timed collection period, with the equation
OD = (U/P)W(U/P)1 (2)
where (U/P)D and (U/P)1 refer to the urine/mid-
point plasma concentration ratios of dextran and in-
ulin, respectively. During this urine collection peri-
od, plasma inulin concentration declined on average
by approximately 30% in all three study groups, and
plasma concentration for dextran molecules with r
= <30 A declined proportionately. For larger dex-
tran molecules, however, the decline in plasma con-
centration approached 20% when r = >40 A.
Plasma renin activity (PRA) and plasma oncotic
pressure () were determined from plasma drawn
immediately preceding the study.
Laboratory deter,ninations. For the calculation
of GFR, we determined inulin concentrations in
plasma and urine by the autoanalyzer method of
Fjelbo and Stamey [19]. This method uses the fruc-
tose-specific reagent resorcinol, and is thus uninflu-
enced by the presence of dextran. The autoanalyzer
method of Harvey and Brothers, which uses Mar-
shall reagent, was used for the determination of
PAH concentration [20]. After gel permeation chro-
matography of plasma and urine was performed,
eluted fractions were assayed for dextran and inulin
concentrations by a modification of the autoanaly-
zer anthrone method of Scott and Melvin [21]. Dex-
tran standards were prepared for assaying the early
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dextran-containing fractions (nos. 32 to 45). Sepa-
rate inulin standards were used for assay of the
smaller inulin molecules (r = 11 to 17 A), which ap-
peared in the later eluted fractions (nos. 48 to 57).
These inulin measurements were used in the calcu-
lation of fractional dextran clearances. To com-
pensate for chloride ion interference in the anthrone
reaction, the chloride content in the standard was
identical to that of the eluted fractions. Albumin
concentration in plasma and urine was determined
by radial immunodiffusion [22]. Unconcentrated
urine was examined in low level plates (Endo-
plates; Albumin Cerebrospinal Fluid Test Kit, Kal-
lestad Labs., Inc.), which permit the measurement of
albumin concentrations over a range of 4 to 100 mgI
dl. Plasma oncotic pressure was measured with an
IL 186 Weil OncometerTM [23], and PRA was deter-
mined by radioimmunoassay with a method pre-
viously described by Haber et al [24].
Chrornato graphic procedures. Dextran 40 in
plasma and urine was separated into narrow frac-
tions (r interval, approximately 2 A) by gel per-
meation chromatography. Two columns were used,
each containing Sephacryl S200 and measuring 91 X
1.6 cm and 94 X 1.6 cm, respectively (Pharmacia
Fine Chemicals AB, Uppsala, Sweden). The eluant
contained 0.3% saline with 0.05% chlorobutanol as
an antimicrobial, and 2.6 ml eluted fractions were
collected with an automatic fractionator (Gilson).
Blue dextran (2 mglml) was used to determine the
void volume (V0) of the columns, and the fractional
volume available to the solute (Kay) was then calcu-
lated for each column from the equation
Kay = (Ve — V0)/(V — V0) (3)
where ye is the elution volume of the solute, and Vt
is the total volume of the gel bed [25].
Each column was calibrated with narrow dextran
fractions Tl0, T40, and T70 (Pharmacia Fine Chem-
icals) of mol wt's 10,000, 40,000, and 70,000 dal-
tons, respectively. From the exponential relation-
ship between Kay and molecular weight, the weight-
average molecular weights (Mw) of the eluted frac-
tions were calculated. The Stokes-Einstein radius
for each dextran fraction was then calculated by the
equation [26]
Radius (A) = 0.33 x Mo463 (4)
Statistical methods. Differences between patient
groups were evaluated with Student's t test for un-
paired data. All results are expressed as the mean
SEM.
Results
Hemodynainic findings (Table 1). Cardiac per-
formance was depressed in all 17 patients with car-
diac failure. Cardiac index averaged 2.3 0.2 liters!
minim2, and the mean ERPF measured by the
biexponential decay of plasma PAH was depressed
to 215 20 mllminll.73 m2. Plasma renin activity,
measured in 14 patients with cardiac failure, was
greatly elevated when compared to our range for su-
Table 1. Hemodynamic findings in patients with cardiac failurea
Patient no.
CI
literslmin/,n2
MAP
m,n Jig
ERPF
,nlI,ninll .73 ni2
PRA
ng/mllhr ,n,n Jig
GFR
,nlIminII .73 m2
1 1.95 75 131 27.6 17.2 126
2 2.31 79 203 — 16.5 67
3 3.67 75 195 20.3 26.9 42
4 — — 293 23.4 26.9 53
5 3.11 80 121 69.4 16.6 30
6 2.59 80 124 18.7 26.3 33
7 3.31 80 239 — 22.0 64
8 2.25 79 286 35.1 24.7 62
9 2.04 68 132 41.7 28.4 27
10 1.90 84 204 15.4 20.8 38
11 2.92 75 326 — 18.8 86
12 — — 344 2.5 17.6 111
13 0.90 65 119 1.9 22.2 45
14 2.15 72 176 4.8 21.8 81
15 — 65 292 2.2 17.1 47
16 0.96 85 151 55.1 24.4 38
17 1.78 74 322 24.0 17.5 29
2.27 76 215 24.4 21.5 58
so 0.80 6 81 20.3 4.1 29
SEM 0.22 2 20 5.4 1.0 7
a Abbreviations are defined as CI, cardiac index; MAP, mean arterial pressure; ERPF, effective renal plasma flow; PRA, plasma renin
activity; ir, plasma oncotic pressure.
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pine sodium-restricted normal subjects (1.9 to 2.8
ng/mllhr), averaging 24.4 5.4 nglml/hr. Systemic
plasma oncotic pressure, which is taken to be the
same as that in the afferent arteriole, averaged 21.5
1.0 mm Hg in patients with cardiac failure, a val-
ue identical with that found in normal supine adults
by Weil et al [23].
Renalfunction. GFR was depressed below that of
normal control subjects in all but two cardiac pa-
tients and averaged 58 7 ml/min/1.73 m2 (Table 1).
Urinary albumin was undetectable in all normal
control subjects and in 9 of the patients with cardiac
failure. In the remaining 8 cardiac patients, urinary
albumin excretion (UalbV) varied between 23 and
499 g!min, averaging 82 35 j.tgImin for the entire
cardiac failure group. By comparison, UajbV (3333
759 gImin) was massively increased in patients
with minimal change nephropathy, exceeding the
corresponding values in cardiac patients by more
than an order of magnitude (P < 0.001) (Table 2).
Urinary dextran clearances and excretion. The
fractional clearance values for dextrans relative to
inulin (6D) in normal control subjects are plotted as a
function of the Stokes-Einstein radius (r) of each
dextran molecule in Fig. 1, Measurable restriction
to dextran (indicated by °D falling below unity) oc-
curred when r > 22 A. With increasing molecular
size, t declined and approached zero for dextrans
with r> 46 A (Table 3). As shown in Fig. 1, similar
values for fractional clearances have been demon-
strated in healthy human adults by others using
both dextrans [27] and another uncharged macroso-
lute, polyvinylpyrrolidone (PVP) [28]. These values
for O or ov differ from those reported in other spe-
cies such as the dog [29] or rat [30], in that they
exceed 0.10 in the dextran r interval 38 to 42 A.
That a lesser degree of restriction to the trans-
glomerular passage of these large dextran molecules
in human adults may be a function of age rather
than species is suggested by the finding that O and
= < 0.10 in the r = 38 to 42 A interval in
healthy infants and children [31-32].
In patients with cardiac failure, mean °Dwas sub-
stantially elevated relative to normal control sub-
jects over the entire range of molecular sizes exam-
ined (Fig. 2). This elevation of 0D achieved statisti-
cal significance in the r interval 28 to 46 A (Table 3).
In striking contrast, 0D in patients with minimal
change nephropathy was depressed below that of
normal control subjects in the r interval 24 to 42 A
(Fig. 2, Table 3).
For a dextran molecule with r = 36 A (D36), which
is the same as that of albumin, mean 0D36 in patients
with cardiac failure was elevated 58% above that of
normal control subjects (0.41 0.03 vs. 0.26
0.01). Because dextran is neither reabsorbed nor se-
creted by the renal tubule, its urinary excretion rate
(UDV) is determined by the filtered load [3]. UDSSV
averaged only 1127 g!min in patients with cardiac
failure compared to 2040 ig!min in normal control
subjects (Table 2). This relative depression in UD36V
resulted from a reduction in filtered load of D36 due
to a combination of low plasma D36 concentration
and depression of GFR. In patients with minimal
change nephropathy, UD36V was also reduced rela-
tive to normal control subjects (1214 86 vs. 2040
205 tg/min) reflecting a 27% depression in 0D36 in
addition to slight reduction in GFR (75 vs. 99 ml!
minll.73 m2).
Discussion
There is growing evidence that hemodynamic fac-
tors may exert important influences on the glomeru-
lar filtration of macromolecules [33]. In general, an
inverse relationship exists between GFR and the
fractional clearance of macromolecules [3—4]. Such
a relationship was clearly demonstrated in our pa-
tients with cardiac failure and lends credence to the
Table 2. Urinary macromolecule excretion in cardiac failures
P,Ib
gidi
UaIbV
pg/nin
PD3
p.g/n1
UV
pg/Pnin
GFR
rn//minI! .73 m2
Normal controls (N = 7) 3.96 ND 83 2040 99
Cardiac failure (N = 17) 3.46 82 57 1127 58
pb NS — <0.05 <0.005 <0.001
Minimal change (N = 7) 2.43 3333 75
P <0.005 <0.001 NS <0.02 NS
Values are means SEM. ND denotes not detectable.
Cardiac failure vs. normal controls
Cardiac failure vs. minimal change nephropathy
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possibility that altered glomerular capillary hemo-
dynamics (rather than changes in the intrinsic per-
meability properties of the glomerular capillary
wall) may be responsible for increased trans-
glomerular passage of macromolecules. The hemo-
dynamic determinants of GFR include glomerular
plasma flow, afferent glomerular oncotic pressure,
and the glomerular transcapillary hydraulic pres-
sure difference [4]. Only plasma oncotic pressure
was measured directly and was within the normal
range. The biexponential plasma decay method for
estimating ERPF is less accurate than the standard
urinary PAH clearance [34]. Nevertheless, the pro-
found depression in ERPF suggests that glomerular
plasma flow was severely depressed in patients with
cardiac failure.
Glomerular capillary pressures and flows cannot
be directly measured in man. It is, therefore, inter-
esting to compare fractional clearances of uncharged
macromolecules in our hyperangiotensinemic cardi-
ac failure patients with those obtained in experi-
mental animals during an angiotensin-Il-induced
depression of renal plasma flow. Although this ex-
perimental maneuver did not significantly increase
the fractional clearance of uncharged PVP mole-
cules in the dog [29], a striking increase in frac-
tional clearance of both PVP and dextrans has been
observed in the rat [9. 16]. In the study by Bohrer
et al in which the determinants of single nephron
GFR were directly measured, fractional dextran
clearances were analyzed with a theoretical model
of restricted macromolecule transport across a
glomerular capillary wall perforated by small pores.
According to this analysis, the angiotensin-Il-in-
duced elevation in fractional dextran clearance could
be entirely attributed to depression of glomerular
plasma flow [9]. Although this seems a likely ex-
planation for our finding in cardiac failure, we can-
not exclude a change in the intrinsic permeability
properties of the glomerular capillary wall. Thus, an
increase in either glomerular pore size or pore den-
sity would be predicted to result in a similar eleva-
tion of the fractional dextran clearance profile [3].
Irrespective of the precise mechanism for the in-
creased transglomerular passage of dextrans, re-
duced UD3GV in cardiac failure indicates that in-
creased UaIbV cannot be explained on the basis of
molecular size alone. At equivalent plasma concen-
trations of D36, the 58% increase in °D36 in cardiac
failure relative to normals would be largely offset by
the approximately 50% decline in GFR. In this
study, UD3BV was significantly less in patients with
cardiac failure than it was in normal control sub-
jects(1127 182 vs. 2040 205 .tg/min,P<0.005).
This difference can be attributed to a lower plasma
D36 concentration, reflecting the use of smaller dex-
tran infusions in some patients with more severe
cardiac failure and possibly an increased volume of
dextran distribution in edematous patients. By con-
trast, mean UaIbV was increased to 82 35 gImin
in these patients, a value eight times higher than
that recently reported for normal subjects [35—36].
Table 3. Fractional dextran clearances in cardiac failures
With dextran radius
18A 20A 22A 24A 26A 28A 30A 32A 34A 36A 38A 40A 42A 44A 46A
Einstein—Stokes Radius, A
Fig. 1. Fractional dextran clearance profile in healthy i'olun-
teers. For comparison, fractional clearances of dextrans (D) [27]
and PVP (Lx) [28] reported from other laboratories are shown.
Normalcontrols 1.00 0.97 0.90 0.80 0.74 0.62 0.55 0.44 0.34 0.26 0.20 0.15 0.11 0.07 0.05(N = 7) ±0.03 ±0.05 ±0.06 ±0.03 ±0.03 ±0.03 ±0.03 ±0.02 ±0.02 ±0.01 ±0.01 ±0.01 ±0.01 ±0.01 ±0.01
Minimalchange 0.93 0.89 0.78 0.68 0.60 0.51 0.41 0.32 0.25 0.19 0.15 0.11 0.08 0.05 0.04(N = 7) ±0.06 ±0.07 ±0.07 ±0.06 ±0.06 ±0.05 ±0.04 ±0.03 ±0.03 ±0.02 ±0.02 ±0.01 ±0.01 ±0.01 ±0.01
P. vs. normal NS NS NS NS NS NS <0.02 <0.01 <0.05 <0.01 <0.05 <0.02 NS NS NS
Cardiacfailure 1.01
±0.04
1.02
±0.08
0.99
±0.09
0.91
±0.07
0.89
±0.08
0.79
±0.07
0.72 0.62 0.51 0.41
±0.05 ±0.04 ±0.04 ±0.03
0.32 0.24
±0.03 ±0.02
0.18
±0.02
0.13
±0.01
0.09
±0.01
P, vs. normal NS NS NS NS NS <0.05 <0.01 <0.001 <0.001 <0.001 <0.001 <0.001 <0.005 <0.001 <0.01
a Vales are the means ± SEM. P values were calculated from Student's I test for unpaired data.
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1.01
0.80.
0.6
0.
0.4
0.2
18 22 26 30 34 38 42 46 50
Einstein—Stokes radius, A
Fig. 2. Fractional dextran clearance profiles in patients with car-
diac failure (A), in normal control subjects (•). and in patients
with minimal change disease (fl).
There are several possible explanations for a se-
lective enhancement of UalbV relative to UDS6V in
cardiac failure. Increased filtration of albumin could
result from impaired glomerular electrostatic bar-
Her function, which has been demonstrated in vari-
ous experimental glomerular injuries associated
with proteinuria [37—38]. Alternately, there is some
evidence to suggest that fractional clearance of neg-
atively charged macromolecules is preferentially
enhanced relative to that of uncharged macromole-
cules when glomerular plasma flow is reduced.
Thus, the fractional clearance of a dextran sulfate
molecule with r = 36 A was increased by 300% dur-
ing angiotensin-Il-induced reduction in glomerular
plasma flow, whereas that of an uncharged dextran
molecule of equivalent size increased by only 50%
[9]. Similarly, Eisenbach et al found albumin con-
centration in the first part of the proximal tubule to
increase 24-fold during angiotensin II infusion rela-
tive to preinfusion levels [10]. In this and other mi-
cropuncture studies, it has also been shown that
when albumin filtration increases, the mechanism
by which the proximal tubule reabsorbs filtered al-
bumin becomes saturated with the result that frac-
tional tubular reabsorption of albumin declines [10,
39-40]. The eightfold increase in mean U51bV in car-
diac failure above normal values may, therefore, re-
flect a disproportionate increase in fractional clear-
ance of anionic albumin due to both increased filtra-
tion and reduced fractional tubular reabsorption,
and could conceivably occur on a hemodynamic
basis.
In the hope that the pathogenesis of albuminuria
in patients with cardiac failure might be clarified,
we compared them to a group of similarly studied
patients with minimal change nephropathy. In the
latter disorder, the only consistent morphologic
change in the glomerular capillary wall, obliteration
of the epithelial foot processes, is common to all
proteinuric disorders and is reversible. In contrast
to cardiac failure, the fractional dextran clearance
profile was depressed relative to normals. Similar
restriction to transglomerular transport of un-
charged macromolecules has been reported in lipoid
nephrosis in children [31] and in puromycin amino-
nucleoside (PAN) nephropathy in rats [37, 41]. In
the latter disorder, widely regarded as an experi-
mental analogue of human minimal change ne-
phropathy, this phenomenon has been associated
with changes in the permeability properties of the
glomerulus, namely reduction in the glomerular ul-
trafiltration coefficient and in pore density [37]. Giv-
en reduction in ERPF (370 31 ml/minl 1.73 m2) in
our patients with minimal change nephropathy, it
seems unlikely that hemodynamic determinants of
GFR could account for the depression of al-
though a minor contribution by the depressed
plasma oncotic pressure (17 1 mm Hg) cannot be
excluded. A change in the permeability properties
of the glomerulus of the type found in PAN ne-
phropathy, however, appears to provide a more
likely explanation for the findings.
As a result of depression of O, mean UDS6V was
also depressed relative to normal control subjects in
minimal change nephropathy. Whereas UDS6V was
similar in minimal change nephropathy and in car-
diac failure, Ua!bV was massively enhanced in the
former, exceeding that in cardiac failure by more
than one order of magnitude. This striking enhance-
ment of urinary excretion, and presumably gb-
merular filtration, of anionic albumin relative to un-
charged dextran in minimal change nephropathy
may reflect loss of electrostatic glomerular barrier
function. A similar discrepancy between the frac-
tional clearances of anionic dextran sulfate and un-
charged dextran has been reported in PAN ne-
phropathy [37]. Sialoprotein, which is thought to be
the glomerular polyanion responsible for the charge
selective properties of the filtration barrier, has
been found to be depleted in both minimal change
and PAN nephropathies [42-43] and is thought to
account for the massive proteinuria in these dis-
orders. Proteinuria in the range found in minimal
change nephropathy has also been reported in car-
diac failure. Such isolated reports, however, are all
from the older literature and were invariably associ-
ated with mercurial diuretic therapy [11—12, 44—46].
Our finding of a more modest rate of urinary albu-
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mm excretion in only 8 of 17 patients with cardiac
failure is in keeping with other larger studies [1—21.
Accordingly, if the charge-selective properties of
the glomerular capillary wall are indeed impaired in
cardiac failure, such impairment is trivial by com-
parison with minimal change nephropathy.
Whether hemodynamic changes alone, on the one
hand, or an increase in glomerular porosity and loss
of electrostatic barrier function on the other, ac-
count for the albuminuria associated with cardiac
failure is difficult to resolve. Although we propose
that reduced glomerular plasma flow may be the
major determinant, a more direct approach in an an-
imal with surface glomeruli and experimental car-
diac failure will be required to characterize more
precisely the altered glomerular permselectivity we
have demonstrated in human cardiac failure.
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